tripeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-12-15. Numbers and descriptions here follow the published literature rather than marketing material.
Copper(II) binds the peptide through four nitrogen donors: the terminal amino group, the imidazole nitrogen of histidine, and two deprotonated amide nitrogens of the peptide backbone. This tetradentate arrangement gives a roughly square-planar geometry, the thermodynamically favoured form near neutral pH. Because the amide nitrogens must lose a proton before they can coordinate, complex formation is strongly pH-dependent, and the fully coordinated species dominates only above mildly acidic conditions. Electronic transitions within the copper d orbital set produce the characteristic blue to violet colour in aqueous solution.
Endogenous GHK occurs in blood plasma, saliva, and urine, and reported plasma concentrations decline with age in several studies. Researchers have proposed that the peptide acts as a copper carrier that delivers the metal to cells and to sites of injury. That transport role is a hypothesis supported by binding measurements and tissue-distribution data rather than a settled mechanism, and the peptide is generally described as a minor contributor to total plasma copper transport. Values reported in wound fluid and certain tissue extracts are higher than in circulating plasma.
The sequence carries three residues in the order glycine, histidine, lysine, which places a small, flexible chain around a single metal centre. Compared with larger copper-binding proteins, the complex is compact and its coordination chemistry can be reproduced with synthetic peptide in a laboratory. Published structural work agrees on the nitrogen donor set but differs in the exact geometry assigned under some conditions, so the arrangement is best treated as well characterised in outline rather than fixed in every detail.
The tripeptide was first isolated from a human plasma filtrate in 1973 during studies of tissue repair factors. Later work detected the free peptide and its copper complex in saliva, urine, and wound fluid, suggesting a natural role in tissue remodeling. Plasma concentrations reported in early literature decline with age, a pattern often cited in discussions of skin aging. Whether these endogenous levels are directly functional or largely incidental remains an open question. The peptide sequence is conserved across mammalian species.
Material described in research and cosmetic supply chains is typically a synthetic peptide supplied as a lyophilized powder. Purity is commonly reported through chromatographic separation, often at 95 percent or higher, while copper content is confirmed by separate elemental analysis. Batch variation in color and solubility can reflect residual counter-ions, moisture, or partial oxidation of the peptide. Because the complex is not a single regulatory entity, specifications differ between suppliers and are not standardized internationally.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Copper(II)-tripeptide complex | One peptide ligand with one coordinated metal centre |
| Peptide sequence | Gly-His-Lys | Three residues written in one-letter notation |
| Free peptide mass | 340.4 g/mol | Metal-free GHK; the complex has a higher mass |
| Appearance | Blue to violet solid or solution | Colour originates from copper d orbital transitions |
| Storage | Desiccated, -20 °C, protected from light | Dry powder is more stable than dissolved material |
Published work on GHK-Cu concentrates largely on cell culture systems rather than whole organisms. Frequently used endpoints include collagen synthesis, expression of matrix metalloproteinases, and migration of fibroblasts. Some reports describe antioxidant behavior, while others stress delivery of copper into cells. These mechanisms are proposed rather than demonstrated, and the relative weight of each pathway is unclear. Human trials are few and generally small, so laboratory findings should not be read as confirmed clinical results.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide backbone consists of glycine, histidine, and lysine joined in that order. Copper is held through the imidazole nitrogen of histidine and the alpha-amino group at the N-terminus, which together produce a square-planar arrangement around the metal center. The solid appears blue to violet, a color that originates from d-d electronic transitions within the copper coordination sphere. The complex is indexed under CAS number 89030-95-5.
The sequence now called GHK was first reported in the early 1970s after isolation from human plasma, where it was noted to influence liver cell behavior in laboratory preparations. Later work described a copper-binding form and its activity in fibroblast and wound-model experiments. Review articles frequently group the substance with other copper peptides. Concentrations in blood appear to fall with age in several small surveys, although the reason for this trend is not settled. Whether such a decline carries functional consequences remains an open question.
Handling practices for the solid material emphasise low temperature and dryness. The lyophilised or powdered form is typically kept at refrigerator or freezer temperatures together with a desiccant. Working solutions are often prepared fresh, because repeated freeze-thaw cycles and extended storage may alter the complex. Glass or inert plastic containers are preferred over materials that could leach metal ions into the preparation. Such practices follow general peptide conventions rather than substance-specific regulations.
Analytical verification commonly relies on high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Spectroscopic methods such as UV-visible absorption and electron paramagnetic resonance can probe the metal centre itself, since the d9 configuration of copper(II) produces characteristic signals. Elemental analysis or plasma-based techniques quantify copper content. Because each method reports a different aspect of the same sample, purity figures are most meaningful when the technique and its detection wavelength are stated alongside the value.
Laboratory characterization of GHK-Cu typically combines separation, spectroscopic, and elemental techniques. Reverse-phase high-performance liquid chromatography is widely used to assess peptide purity, often with ultraviolet detection near the copper-related absorption band or with mass spectrometry for identity confirmation. Because the molecule contains copper, elemental methods such as inductively coupled plasma mass spectrometry or atomic absorption spectroscopy are used to quantify metal content and confirm stoichiometry. No single universal pharmacopeial monograph exists for GHK-Cu. Laboratories therefore validate their own methods, and reported purity values depend on the chosen assay and calibration standards.
Stability of GHK-Cu is influenced by light, oxygen, moisture, pH, and temperature. Solid material is generally kept desiccated and frozen to reduce hydrolysis and oxidation, while aqueous solutions are best prepared fresh or stored cold in aliquots. Repeated freeze-thaw cycles can promote aggregation, precipitation, or peptide degradation. Copper coordination may change under strongly acidic or alkaline conditions, potentially altering the complex's spectroscopic properties. Published long-term stability data for specific matrices, such as cosmetic emulsions or biological buffers, are limited, so shelf-life claims should be treated as formulation-specific rather than universal.
Large hardened nuclear weapon storage areas were built across European countries in anticipation of local US and European forces falling back as the conventional NATO defense from the Soviet Union, named REFORGER, was believed to only be capable of stalling the Soviets for a short time.
Leroy Hood is a member of the National Academy of Sciences (NAS, 1982), the National Academy of Engineering (2007), the National Academy of Medicine (formerly the Institute of Medicine, 2003), and the National Academy of Inventors (2012). He is one of only 15 scientists ever elected to all three national academies. He is also a member of the American Academy of Arts and Sciences (1982), a member of the American Philosophical Society (2000), a fellow of the American Society for Microbiology, and a charter fellow of the National Academy of Inventors (2012).
== History == Perhaps the most famous person who exemplified the appearance of untreated congenital growth hormone deficiency was Charles Sherwood Stratton (1838–1883), who was exhibited by P. T. Barnum as General Tom Thumb, and married Lavinia Warren. Pictures of the couple show the typical adult features of untreated severe growth hormone deficiency. Despite the severe shortness, limbs and trunks are proportional. By the middle of the twentieth century, endocrinologists understood the clinical features of growth hormone deficiency. GH is a protein hormone, like insulin, which had been purified from pig and cow pancreases for treatment of type 1 diabetes since the 1920s. However, pig and cow GH did not work at all in humans, due to greater species-to-species variation of molecular structure (i.e., insulin is considered more "evolutionarily conserved" than GH).
Mark Twain was a prominent contemporaneous critic of Eddy's. His first article about Christian Science was published in Cosmopolitan in October 1899. Another three appeared in 1902–1903 in North American Review, then a book, Christian Science (1907). He also wrote a satirical story, "The Secret History of Eddypus, the World Empire" (1901–1902), in which Christian Science replaces Christianity and Eddy becomes the Pope. Twain described Eddy as "[g]rasping, sordid, penurious, famishing for everything she sees—money, power, glory—vain, untruthful, jealous, despotic, arrogant, insolent, pitiless where thinkers and hypnotists are concerned, illiterate, shallow, incapable of reasoning outside of commercial lines, immeasurably selfish." Science and Health he called "strange and frantic and incomprehensible and uninterpretable," and argued that Eddy had not written it herself. "There is nothing in Christian Science that is not explicable," he wrote, "for God is one, Time is one, Individuality is one, and may be one of a series, one of many, as an individual man, individual horse; whereas God is one, not one of a series, but one alone and without an equal." Eddy apart, Twain felt ambivalent toward mind-cure, arguing that "the thing back of it is wholly gracious and beautiful." His daughter Clara Clemens became a Christian Scientist and wrote a book about it, Awake to a Perfect Day (1956). Albert Bigelow Paine, Twain's biographer, quotes Twain as satirically saying this about Mary Bakery Eddy: "Christian Science is humanity’s boon.
Sources: en.wikipedia.org
=== No development reported === AD-6626 – aldehyde dehydrogenase 2 (ALDH2) inhibitor – alcoholism AM-6527 (AM6527) – cannabinoid CB1 receptor antagonist – substance-related disorders Amitifadine (DOV-21947; EB-1010) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) – alcoholism, opioid-related disorders, smoking withdrawal, substance-related disorders Arbaclofen extended release – GABAB receptor agonist – opioid-related disorders BMB-101 – serotonin 5-HT2 receptor agonist – opioid-related disorders Bupropion/mecamylamine (INT-0003; QuitPak) – combination of bupropion (norepinephrine–dopamine reuptake inhibitor (NDRI), nicotinic acetylcholine receptor negative allosteric modulator) and mecamylamine (non-selective nicotinic acetylcholine receptor antagonist) – smoking withdrawal Cannabidiol (CBD; cannabidiol transderma/topical gel/patch; Zygel; ZYN-002) – cannabinoid/various actions – alcoholism, substance-related disorders CM-1212 – undefined mechanism of action – alcoholism, substance-related disorders CPP-115 – GABA transaminase (GABA-T) inhibitor – substance-related disorders CT-044 analogues - CERSCI Therapeutics – reactive oxygen species (ROS) inhibitors (CT-044 analogues) – opioid-related disorders CX-717 (CX717) – AMPA receptor positive allosteric modulator (ampakine) – substance-related disorders Cyproheptadine/prazosin (KT-110; Periactine/Alpress) – combination of cyproheptadine (various actions) and prazosin (α1-adrenergic receptor antagonist) – substance-related disorders DCR-AUD (DCR-A1203; NN-6020) – aldehyde dehydrogenase 2 (ALDH2) inhibitor, RNA interference – alcoholism Dimethyltryptamine (DMT; EBRX-101) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, and serotonergic psychedelic – smoking withdrawal GLWL-01 – ghrelin O-acyltransferase (GOAT) inhibitor – alcoholism GSK-598809 (GSK598809) – dopamine D3 receptor antagonist – smoking withdrawal, substance-related disorders GSK-1521498 – μ-opioid receptor inverse agonist – cocaine-related disorders GTS-21 (DMXB-A; DMBX-anabaseine) – nicotinic acetylcholine receptor agonist – smoking withdrawal Icalcaprant (ABBV-1354; CVL-354) – κ-opioid receptor antagonist – substance-related disorders Levodopa (CVT-301; CXG-89; Inbrija) – dopamine precursor (non-selective dopamine receptor agonist) – smoking withdrawal Mazindol controlled release (NLS-0; NLS-1; NLS-10; NLS-13; NLS-2; Nolazol; Quilience) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) – opioid-related disorders Midomafetamine (MDMA; ecstasy) – serotonin–norepinephrine–dopamine releasing agent (SNDRA), serotonin 5-HT2 receptor agonist, and entactogen – substance-related disorders Mifepristone (C-1073; Corlux; Corluxin; Korlym; Mifegyne; Mifeprex; RU-38486; RU-486) – glucocorticoid, progesterone, and androgen receptor antagonist – smoking withdrawal Modafinil oral (ASB) – atypical dopamine reuptake inhibitor (DRI) – cocaine-related disorders Naloxone nasal spray (-12; LT-20; LT-21; LT-22; Naloxon B; Narcan Nasal Spray; OPNT-001) – μ-opioid receptor antagonist – cocaine-related disorders, substance-related disorders Nalmefene implant (nalmefene six-month implant) – μ-opioid receptor antagonist, κ-opioid receptor weak partial agonist – opioid-related disorders Naloxone buccal/intransal gel (Exonal) – opioid receptor antagonist – opioid-related disorders Nicotine abuse vaccine (Niccine) – nicotinic acetylcholine receptor agonist – smoking withdrawal Nicotine/cannabidiol chewing gum (nicotine/CBD; CVSI-007) – combination of nicotine (nicotinic acetylcholine receptor agonist) and cannabidiol (CBD) (cannabinoid/various actions) – smoking withdrawal Noribogaine derived therapeutic – various actions (noribogaine derivative) – opioid-related disorders OMS-405 (OMS405) – PPARγ agonist – alcoholism Ondansetron (AD-04) – serotonin 5-HT3 receptor antagonist – opioid-related disorders, smoking withdrawal Ondansetron/topiramate (AD-01; AD/TO-01) – combination of ondansetron (serotonin 5-HT3 receptor antagonist) and topiramate (various actions) – alcoholism Ondelopran (LY-2196044; Odelepan; Odelepran; OpRA) – opioid receptor antagonist – alcoholism OPNT-005 (OPNT005; adjuvanted heroin analogue vaccine; diamorphine analogue vaccine; heroin vaccine) – immunostimulant (vaccine against heroin) – heroin-related disorders PF-5402536 (NIC7-001; PF-5402536) – immunostimulant (smoking vaccine) – smoking withdrawal Pomaglumetad methionil (DB103; LY-2140023; LY-2812223; LY-404039 prodrug) – metabotropic glutamate mGlu2 and mGlu3 receptor receptor agonist (pomaglumetad prodrug) – substance-related disorders PPL-103 – μ-opioid receptor agonist, δ-opioid receptor agonist, κ-opioid receptor agonist – substance-related disorders Pregnenolone methyl ether (3β-methoxypregnenolone; MAP-4343) – microtubule-associated protein (MAP) stimulant and tubulin polymerization promoter – substance-related disorders Psilocybin (MYCO-001; MYCO-003) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, and serotonergic psychedelic – substance-related disorders PT-150 (PT150; ORG-34517; SCH-900636) – androgen and glucocorticoid receptor antagonist – alcoholism Research programme: alcoholism therapeutics - ADial Pharmaceuticals – various actions – alcoholism Research programme: allosteric modulators - Addex Therapeutics – various actions – substance-related disorders Research programme: GPCR modulators - Nxera Pharma – various actions – cocaine-related disorders, substance-related disorders Research programme: nociceptin receptor agonists - Astraea Therapeutics – nociceptin receptor agonist, opioid receptor agonist – alcoholism, substance-related disorders Research programme: smoking cessation therapies - Ophidion – smoking withdrawal – nicotinic acetylcholine receptor agonists Research programme: tryptamine based therapeutics - PsyBio Therapeutics – serotonin 5-HT2A receptor agonists – substance-related disorders RTI-598929 – μ-opioid receptor antagonist and κ-opioid receptor antagonist – heroin-related disorders Saracatinib (AZD-0530) – Src-family kinase inhibitor – alcoholism SBP-9330 – metabotropic glutamate mGlu2 receptor modulator – smoking withdrawal SEL-068 (tSVP; immunomodulatory nanoparticle vaccine for smoking cessation) – immunomodulator (smoking vaccine) – smoking withdrawal Serdexmethylphenidate (KP-484; KP-1077; KP-1077H; KP-1077IH; KP-1077N; KP-879) – norepinephrine–dopamine reuptake inhibitor (NDRI) (dexmethylphenidate prodrug) – substance-related disorders TRV-734 (TRV734) – μ-opioid receptor biased agonist – opioid-related disorders VDM-001 – opioid receptor antagonist – alcoholism, opioid-related disorders Zolunicant (18-methoxycoronaridine; 18-MC; MM-110) – α3β4 nicotinic acetylcholine receptor antagonist – substance-related disorders
Boris Savinkov, leader of the organization Phlegont Klepikov, secretary and treasurer Colonel Alexander Perkhurov, chief of staff Colonel Karl Gopper, head of military personnel Colonel Stradetsky, liaison with the Volunteer Army Colonel Friedrich Briedis, responsible for intelligence, counterintelligence, and anti-Bolshevik propaganda among the Latvian Riflemen Doctor Aksanin (Nikolai Sergeyevich Grigoryev), head of the provincial and propaganda section Captain Alexander Vilenkin, head of the cavalry center Captain Schroeder, head of the artillery center Alexander Dikgof-Derenthal, who helped maintain contact with foreign missions Lyubov Dikgof, secretary to Savinkov
May 10: Circular from the Keeper of the Seals specifying that marriage age dispensations can only apply to girls over 14 years old (except in cases of pregnancy) and boys over 17 years old. August 20: Upon dismissal or illness of a Royal Printing Office official, the retirement pension is defined, with a lower amount for women than for men. A widow of such an official may, in certain cases, be entitled to a survivor's pension. December 8: Prohibition on women directing theatrical troupes. 1825
The programme is also expected to create over 4 million jobs in the next 4 years (2.5 million direct jobs and 1.5 million indirect jobs). Some economists have criticised the plan, citing Brazil's poor track record of investment quality and worries regarding fiscal responsibility. Of the energy investments, 343 billion will be made through Petrobras, a state-owned corporation notable for its involvement in a corruption scandal during Lula's previous presidency.
Since their construction and decoration between the 4th and 8th centuries CE, the Kizil Caves have suffered numerous periods of religious vandalism and decay. Western archaeologists orchestrated the massive sampling on the best remaining works of art in the early 20th century. Aside from their colonial outlook, one of their alleged motivations was to protect these works of arts from vandalism due to Islamic iconoclasm and the depredations of treasure hunters. Most of the dismantled panels were sent to the Museum für Indische Kunst, Berlin, Germany, but many were destroyed in World War II, with only photographs or drawings remaining in the best cases. A significant number of the murals were also captured by the Soviets in Berlin, and turned up recently in the Hermitage Museum. In more recent times, the Red Guards also contributed to the destruction of the site, and last but not least, the transformation of the site for touristic purposes since 2005 has led to the disfigurement of many caves and the irretrievable loss of archaeological knowledge. Today, none of the caves can be said to have remained entirely intact, although many remain quite impressive.
Sources: en.wikipedia.org
It consists of a three-amino-acid peptide, glycine-histidine-lysine, bound to one copper(II) ion. The peptide supplies four nitrogen donor atoms, and the resulting complex is stable in neutral aqueous solution. The metal-free peptide is usually called GHK.
The three letters are the standard one-letter codes for glycine, histidine, and lysine. The suffix -Cu indicates the coordinated copper ion. Cosmetic ingredient lists often use the alternative name copper tripeptide-1 for the same complex.
No. Free GHK is the peptide alone, while GHK-Cu contains a bound copper atom. The two differ in colour, charge, and binding behaviour, so any study that measures copper delivery must state which form was used.
It is a complex of the tripeptide glycyl-L-histidyl-L-lysine with a copper(II) ion. The peptide coordinates the metal through its histidine, amino terminus, and an amide nitrogen. It is often listed simply as copper tripeptide-1.